Ransys Tablet 20 mg

9 inc. Vat

Ransys Tablet
Olmesartan Medoxomil
20 mg
Healthcare Pharmaceuticals Ltd.
Unit Price

Categories: ,
Barakah Medicine


(5 Reviews)


Olmesartan Medoxomil is indicated for the treatment of hypertension. It may be used alone or in combination with
other antihypertensive agents.
Angiotensin-II formed from angiotensin-I in a reaction catalyzed by angiotensin-converting enzyme (ACE), is a
potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important
component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex.
Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin-II by selectively blocking the
binding of angiotensin-II to the AT 1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland). Invitro-binding studies indicate that Olmesartan is a reversible & competitive inhibitor of AT 1 receptor. Olmesartan
does not inhibit ACE (kinase-I, the enzyme that converts angiotensin-I to angiotensin-II and degrades bradykinin).
Dosage must be individualized. The usual recommended starting dose of Olmesartan is 20 mg once daily when used
as monotherapy in patients who are not volume-contracted. For patients requiring further reduction in blood
pressure after 2 weeks of therapy, the dose of Olmesartan may be increased to 40 mg. Doses above 40 mg do not
appear to have a greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
No initial dosage adjustment is recommended for elderly patients, for patients with moderate to marked renal
impairment (creatinine clearance <40 ml/min) or with moderate to marked hepatic dysfunction. For patients with
possible depletion of intravascular volume (e.g. patients treated with diuretics, particularly those with impaired renal
function), Olmesartan should be initiated under close medical supervision and consideration should be given to use of
a lower starting dose. Olmesartan may be administered with or without food.

* চি কি ৎসকে র পরা মর্শ মোর্শমো তা বে ক ঔষধ সে বন করুন’
With medicine: No significant drug interactions were reported in which Olmesartan was co-administered.
With food & others: Food does not affect the bioavailability of Olmesartan.
Olmesartan is contraindicated in patients who are hypersensitive to any component of this product.
Common: The most common side effects include Back pain, bronchitis, creatine phosphokinase increased, diarrhea,
headache, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, and
Rare: Chest pain, peripheral edema, arthritis.
Pregnancy: When pregnancy is detected, discontinue this product as soon as possible. When used in pregnancy
during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and
even death to the developing fetus.
Nursing Mothers: It is not known whether Olmesartan is excreted in human milk, but Olmesartan is secreted at low
concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a
decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance
of the drug to the mother.
Precautions &Warnings
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be
anticipated in susceptible individuals treated with olmesartan medoxomil. In patients whose renal function may
depend upon the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart
failure), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been
associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. Similar results
may be anticipated in patients treated with olmesartan medoxomil.
Use in Special Populations
Paediatric use: Safety and effectiveness in paediatric patients have not been established.
Symptoms: There is no experience of overdose with Olmesartan. The most likely effects of olmesartan medoxomil
overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal)
stimulation occurred.
Treatment: If intake is recent, gastric lavage or induction of emesis may be considered. Clinically significant

hypotension due to an overdose of Olmesartan requires the active support of the cardiovascular system, including
close monitoring of heart and lung function, the elevation of the extremities, and attention to circulating fluid volume
and urine output.
Angiotensin-ll receptor blocker
Store in cool & dry place below 30ºC, protect from light & moisture. Keep out of the reach of children.


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Vendor Information

  • Store Name: Barakah Medicine
  • Vendor: Barakah Medicine
  • 5.00 rating from 5 reviews
    Rated 5.00 out of 5 based on 5 customer ratings
Join Waitlist We will inform you when the product arrives in stock. Please leave your valid email address below.
Scan the code